Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
Blood · 2023
DOI: 10.1182/blood.2022016205 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood, 2023. Verfasst von Frank Cichocki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Minnesota, Minneapolis, MN. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Neoplasms. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
The development of methods to derive induced pluripotent stem cells (iPSCs) has propelled stem cell research, and has the potential to revolutionize many areas of medicine, including cancer immunotherapy. These cells can be propagated limitlessly and can differentiate into nearly any specialized cell type. The ability to perform precise multigene engineering at the iPSC stage, generate master cell lines after clonal selection, and faithfully promote differentiation along natural killer (NK) cells and T-cell lineages is now leading to new opportunities for the administration of off-the-shelf cytotoxic lymphocytes with direct antigen targeting to treat patients with relapsed/refractory cancer. In this review, we highlight the recent progress in iPSC editing and guided differentiation in the development of NK- and T-cell products for immunotherapy. We also discuss some of the potential barriers that remain in unleashing the full potential of iPSC-derived cytotoxic effector cells in the adoptive transfer setting, and how some of these limitations may be overcome through gene editing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, University of Minnesota, Minneapolis, MN.
- Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY.
- Immunology Program, Sloan Kettering Institute, New York, NY.
ORCID-Profile: Frank Cichocki, Sjoukje J C van der Stegen
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Cichocki, F., van der Stegen, S. J. C., & Miller, J. S. (2023). Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies. Blood. https://doi.org/10.1182/blood.2022016205
Vancouver
Cichocki F, van der Stegen SJC, Miller JS. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies. Blood. 2023. doi:10.1182/blood.2022016205
BibTeX
@article{Cichocki2023,
author = {Cichocki, Frank and van der Stegen, Sjoukje J C and Miller, Jeffrey S},
title = {Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022016205}
}
EUVIMED